Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

[1]  K. Loughlin,et al.  Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. , 2015, The Journal of urology.

[2]  Giulio Caracciolo,et al.  Surface chemistry and serum type both determine the nanoparticle-protein corona. , 2015, Journal of proteomics.

[3]  Bertrand Z. Yeung,et al.  Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[4]  J. Au,et al.  Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors. , 2014, Current cancer drug targets.

[5]  L. Ouyang,et al.  Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells. , 2013, Oncology Research.

[6]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[7]  S. Fulda,et al.  Survivin as a prognostic/predictive marker and molecular target in cancer therapy. , 2012, Current medicinal chemistry.

[8]  Ze Lu,et al.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.

[9]  J. Au,et al.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. , 2011, Molecular pharmaceutics.

[10]  Weihong Wang,et al.  Survivin and pancreatic cancer. , 2011, World journal of clinical oncology.

[11]  Y. Lei,et al.  Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance , 2010, Molecular and Cellular Biochemistry.

[12]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[13]  Chen Yang,et al.  Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[14]  T. Park,et al.  siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.

[15]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[16]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[17]  Ze Lu,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[18]  C. Chen,et al.  Time-and concentration-dependent penetration of doxorubicin in prostate tumors , 2001, AAPS PharmSci.

[19]  R. Qin,et al.  siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine Chemosensitivity , 2008, Digestive Diseases and Sciences.

[20]  S. Akhtar,et al.  Nonviral delivery of synthetic siRNAs in vivo. , 2007, The Journal of clinical investigation.

[21]  J. Au,et al.  Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.

[22]  O. Boerman,et al.  INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES , 2006, Drug Metabolism and Disposition.

[23]  Z. Dai,et al.  Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. , 2006, World journal of gastroenterology.

[24]  Myung Ah Lee,et al.  Survivin expression and its clinical significance in pancreatic cancer , 2005, BMC Cancer.

[25]  S. Miyatake,et al.  Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. , 2005, Surgery.

[26]  J. Au,et al.  Formulating Paclitaxel in Nanoparticles Alters Its Disposition , 2005, Pharmaceutical Research.

[27]  B. Vincenzi,et al.  Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients , 2005, British Journal of Cancer.

[28]  D. Levison,et al.  The assessment of cellular proliferation by immunohistochemistry: A review of currently available methods and their applications , 1992, The Histochemical Journal.

[29]  S. Miyatake,et al.  Survivin expression is a prognostic marker in pancreatic cancer patients. , 2004, Surgery.

[30]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[31]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[32]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[33]  M. Wientjes,et al.  Clinical aspects of drug delivery to tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[34]  M. Wientjes,et al.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. , 2001, The Journal of pharmacology and experimental therapeutics.

[35]  Naoki Watanabe,et al.  Survivin as a Radioresistance Factor in Pancreatic Cancer , 2000, Japanese journal of cancer research : Gann.

[36]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[37]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[38]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[39]  K. Bhalla,et al.  Characterization of a human myeloid leukemia cell line highly resistant to taxol. , 1994, Leukemia.